Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Ian Crosbie

Chief Executive Officer

Company Overview

“Sequana Medical is at an exciting phase in its development with clear ambitions to accelerate its commercial growth and innovation. We continue to invest in our alfapump® and DSR® technologies to bring these innovative treatment options to a broader patient group and address important unmet medical needs, while creating value for shareholders.”

Share Price

SEQUANA MEDICAL

ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33

EURO 22.40

XXXXX.XX

+2.18%

For more information, please consult Euronext

Investor Tool Kit

2022 Annual Report

Download .pdf

Investor presentation

Download .pdf

6 questions to CEO Ian Crosbie

Financial Calendar

March 28, 2024

2023 full year results

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES